Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer

Keyphrases

• Phase II Study 100%
• Bevacizumab 100%
• Small Cell Lung Cancer 100%
• Irinotecan 100%
• Hematologic 66%
• Chemoresistant 66%
• Overall Response Rate 66%
• Monoclonal Antibody 33%
• Proteinuria 33%
• Hepatic Function 33%
• Renal Function 33%
• Treatment Response 33%
• Computed Tomography 33%
• Treatment Discontinuation 33%
• Response Evaluation 33%
• Am(III) 33%
• Neutropenia 33%
• 4-cycle 33%
• Cisplatin 33%
• Etoposide 33%
• Stable Disease 33%
• Duration of Response 33%
• Irradiation 33%
• Disease Control Rate 33%
• Median Progression-free Survival 33%
• Median Overall Survival 33%
• Nonhematologic 33%
• Adverse Reactions 33%
• Efficacy-toxicity 33%
• Low Toxicity 33%
• Historical Controls 33%
• Number of Cycles 33%
• ECOG Performance Status 33%
• Consecutive Cycles 33%
• Extensive-stage SCLC 33%
• DNA Topoisomerase Inhibitors 33%

Medicine and Dentistry

• Small Cell Lung Cancer 100%
• Bevacizumab 100%
• Irinotecan 100%
• Disease 50%
• Adverse Event 25%
• Kidney Function 25%
• Proteinuria 25%
• Monoclonal Antibody 25%
• Progression Free Survival 25%
• Treatment Response 25%
• Overall Survival 25%
• Computer Assisted Tomography 25%
• Neutropenia 25%
• Vasculotropin 25%
• Etoposide 25%
• Liver Function 25%
• Cisplatin 25%
• Topoisomerase Inhibitor 25%
• Electrocorticography 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Bevacizumab 100%
• Small Cell Lung Cancer 100%
• Irinotecan 100%
• Disease 50%
• Adverse Event 25%
• Proteinuria 25%
• Monoclonal Antibody 25%
• Overall Survival 25%
• Progression Free Survival 25%
• Neutropenia 25%
• Vasculotropin 25%
• Cisplatin 25%
• Etoposide 25%
• DNA Topoisomerase Inhibitor 25%